These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 27056241)

  • 21. PD-1 Blockade in Melanoma: A Promising Start, but a Long Way to Go.
    Bhatia S; Thompson JA
    JAMA; 2016 Apr; 315(15):1573-5. PubMed ID: 27092829
    [No Abstract]   [Full Text] [Related]  

  • 22. Severe bullous pemphigoid associated with pembrolizumab therapy for metastatic melanoma with complete regression.
    Rofe O; Bar-Sela G; Keidar Z; Sezin T; Sadik CD; Bergman R
    Clin Exp Dermatol; 2017 Apr; 42(3):309-312. PubMed ID: 28211077
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The place of PD-1 inhibitors in melanoma management.
    Bowyer S; Lorigan P
    Lancet Oncol; 2015 Aug; 16(8):873-4. PubMed ID: 26115798
    [No Abstract]   [Full Text] [Related]  

  • 24. Antiphospholipid Syndrome Following Pembrolizumab Treatment of Stage IIIB Unresectable Melanoma.
    Sanchez A; Montaudie H; Bory P; Belgodere X; Passeron T; Lacour JP; Picard A
    JAMA Dermatol; 2018 Nov; 154(11):1354-1356. PubMed ID: 30326507
    [No Abstract]   [Full Text] [Related]  

  • 25. The safety of anti PD-1 therapeutics for the treatment of melanoma.
    Ramelyte E; Schindler SA; Dummer R
    Expert Opin Drug Saf; 2017 Jan; 16(1):41-53. PubMed ID: 27737598
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes of patients with non-melanoma solid tumours receiving self-funded pembrolizumab at Chris O'Brien Lifehouse.
    Lomax AJ; Beith J; Bhadri V; Boyer M; Grimison P; Horvath LG; Kao S; Tattersall M; Thomas D; McNeil C
    Intern Med J; 2016 Dec; 46(12):1392-1398. PubMed ID: 27554283
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Autoimmune endocrinopathies induced by immunomodulating antibodies in the treatment of cancer].
    Iglesias P; Soria A; Díez JJ
    Med Clin (Barc); 2015 Sep; 145(6):264-8. PubMed ID: 25851909
    [No Abstract]   [Full Text] [Related]  

  • 28. Pembrolizumab (Keytruda°) and metastatic or inoperable melanoma.
    Prescrire Int; 2017 May; 26(182):118-119. PubMed ID: 30730667
    [No Abstract]   [Full Text] [Related]  

  • 29. Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma.
    Hersey P; Gowrishankar K
    Future Oncol; 2015; 11(1):133-40. PubMed ID: 25572788
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Two cases of immune thrombocytopenia associated with pembrolizumab.
    Le Roy A; Kempf E; Ackermann F; Routier E; Robert C; Turpin A; Marabelle A; Mateus C; Michot JM; Lambotte O
    Eur J Cancer; 2016 Feb; 54():172-174. PubMed ID: 26687374
    [No Abstract]   [Full Text] [Related]  

  • 31. Definite regression of cutaneous melanoma metastases upon addition of topical contact sensitizer diphencyprone to immune checkpoint inhibitor treatment.
    Gulati N; Carvajal RD; Postow MA; Wolchok JD; Krueger JG
    Exp Dermatol; 2016 Jul; 25(7):553-4. PubMed ID: 27061281
    [No Abstract]   [Full Text] [Related]  

  • 32. Pembrolizumab-induced polymyalgia rheumatica in two patients with metastatic melanoma.
    Garel B; Kramkimel N; Trouvin AP; Frantz C; Dupin N
    Joint Bone Spine; 2017 Mar; 84(2):233-234. PubMed ID: 27133763
    [No Abstract]   [Full Text] [Related]  

  • 33. Melanoma Brain Metastasis Pseudoprogression after Pembrolizumab Treatment.
    Cohen JV; Alomari AK; Vortmeyer AO; Jilaveanu LB; Goldberg SB; Mahajan A; Chiang VL; Kluger HM
    Cancer Immunol Res; 2016 Mar; 4(3):179-82. PubMed ID: 26701266
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A case of arthritis under pembrolizumab.
    Salmon JH; Lambrecht I; Brochot P; Grange F
    Joint Bone Spine; 2017 Mar; 84(2):243-244. PubMed ID: 27118015
    [No Abstract]   [Full Text] [Related]  

  • 35. The safety of pembrolizumab in metastatic melanoma and rheumatoid arthritis.
    Puri A; Homsi J
    Melanoma Res; 2017 Oct; 27(5):519-523. PubMed ID: 28817445
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Setting the bar for adjuvant treatment of melanoma.
    Sondak VK; Gibney GT
    Lancet Oncol; 2014 May; 15(6):547-8. PubMed ID: 24745697
    [No Abstract]   [Full Text] [Related]  

  • 37. Pembrolizumab superior to ipilimumab in melanoma.
    Cancer Discov; 2015 Jun; 5(6):568. PubMed ID: 25895921
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Could knee inflammatory synovitis be induced by pembrolizumab?
    Mahmoud F; Wilkinson JT; Gizinski A; Viswamitra S; Gokden N; Vander Schilden J
    J Oncol Pharm Pract; 2018 Jul; 24(5):389-392. PubMed ID: 28355971
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inverse Psoriasiform Eruption During Pembrolizumab Therapy for Metastatic Melanoma.
    Totonchy MB; Ezaldein HH; Ko CJ; Choi JN
    JAMA Dermatol; 2016 May; 152(5):590-2. PubMed ID: 26675815
    [No Abstract]   [Full Text] [Related]  

  • 40. [Treating metastatic melanoma: Risk management].
    Lebbe C; Robert C
    Ann Dermatol Venereol; 2017 Jan; 144(1):3-5. PubMed ID: 28063593
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.